KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) FCF Margin: 2009-2025

Historic FCF Margin for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to 0.30%.

  • Neogenomics' FCF Margin rose 123.00% to 0.30% in Q3 2025 from the same period last year, while for Sep 2025 it was -2.40%, marking a year-over-year increase of 94.00%. This contributed to the annual value of -5.15% for FY2024, which is 4.00% up from last year.
  • As of Q3 2025, Neogenomics' FCF Margin stood at 0.30%, which was down 96.07% from 7.72% recorded in Q2 2025.
  • Neogenomics' 5-year FCF Margin high stood at 7.72% for Q2 2025, and its period low was -31.80% during Q1 2022.
  • Moreover, its 3-year median value for FCF Margin was -1.05% (2024), whereas its average is -4.87%.
  • In the last 5 years, Neogenomics' FCF Margin tumbled by 2,088bps in 2021 and then surged by 1,934bps in 2022.
  • Quarterly analysis of 5 years shows Neogenomics' FCF Margin stood at -25.26% in 2021, then skyrocketed by 1,934bps to -5.93% in 2022, then soared by 1,282bps to 6.90% in 2023, then tumbled by 794bps to -1.05% in 2024, then skyrocketed by 123bps to 0.30% in 2025.
  • Its last three reported values are 0.30% in Q3 2025, 7.72% for Q2 2025, and -17.75% during Q1 2025.